Wednesday, June 10, 2026

biotech Β· Neuroblastoma Β· Hyperinflammation, Sepsis Β· AXIM

AXIM Biotechnologies

AXIM Biotechnologies clinical programs β€” 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

18 East 50th Street, 5 Floor, New York, NY 10022, US HQ
2011 Founded
7 Employees
Public company Type
AXIM Β· NYSE Ticker
Company details
Status
Public
HQ
18 East 50th Street, 5 Floor, New York, NY 10022, US
Founded
2011
Employees
7
Programs
20
Drugs
52
Patents
138
Intelligence Β· Clinical Programs

AXIM Biotechnologies projects

3 ClinicalTrials.gov programs sponsored by AXIM Biotechnologies.

AXIM Biotechnologies has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. INFLUENCE

    AXIM BIOTECHNOLOGIES, INC.

    B-cell Acute Lymphoblastic Leukemia

    phase 3 small molecule active

    1 trial
  2. IVEMEND for Delayed chemotherapy induced na…

    AXIM BIOTECHNOLOGIES, INC.

    Delayed chemotherapy induced nausea and vomiting (CINV)

    phase 3 small molecule active

    1 trial
  3. SP_MH19PRO

    AXIM BIOTECHNOLOGIES, INC.

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does AXIM Biotechnologies have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.